US · TVTX
Travere Therapeutics, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Diego, CA 92130
- Website
- travere.com
Price · as of 2025-12-31
$44.12
Market cap 2.67B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $56.57 | +28.22% |
| Intrinsic Value(DCF) | $15,446.31 | +34,909.77% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | $5.40 | ||||
| 2013 | $19.29 | ||||
| 2014 | $14.76 | ||||
| 2015 | $15.01 | $143.66 | $5.76 | $26.38 | $877.80 |
| 2016 | $19.68 | $44.27 | $4.65 | $1.82 | $0.00 |
| 2017 | $25.85 | $242.69 | $515.57 | $0.00 | $0.00 |
| 2018 | $21.05 | $165.66 | $5.14 | $0.00 | $0.00 |
| 2019 | $15.02 | $19.88 | $2.17 | $0.00 | $0.00 |
| 2020 | $28.74 | $30.90 | $0.08 | $0.00 | $0.00 |
| 2021 | $24.01 | $33.44 | $0.62 | $0.00 | $72.26 |
| 2022 | $20.73 | $46.81 | $0.00 | $0.00 | $35.51 |
| 2023 | $8.66 | $16.93 | $0.00 | $0.00 | $0.00 |
| 2024 | $18.09 | $26.41 | $47.81 | $0.00 | $0.00 |
| 2025 | $29.53 | $56.57 | $49,144.04 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Travere Therapeutics, Inc.'s (TVTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $56.57
- Current price
- $44.12
- AI upside
- +28.22%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$15,446.31
+34,909.77% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TVTX | Travere Therapeutics, Inc… | $44.12 | 2.67B | +28% | +34,910% | — | — | -103.12 | 22.94 | 5.37 | 118.84 | — | 2744.19 | 85.51% | -12.80% | -10.24% | -29.38% | -59.63% | -4.26% | 2.86 | -5.85 | 2.74 | 2.52 | 10.61 | -8627.00% | 11045.00% | -11116.00% | 1.43% | 0.24 | 35.86% | 0.00% | 0.00% | 4.07% | -42.03 | 69.88 | 5.38 | 0.84 |
| AAPG | ASCENTAGE PHARMA GROUP IN… | $24.00 | 557.78M | -51% | -67% | — | — | -27.16 | 40.63 | 10.95 | -46.99 | — | 65.65 | 97.03% | -37.70% | -41.34% | -243.53% | -49.87% | -15.45% | 6.32 | -5.74 | 1.26 | 1.14 | -1.82 | -8979.00% | 34177.00% | -8267.00% | -1.26% | -0.10 | -18.30% | 0.00% | 0.00% | 2.74% | -30.20 | -82.32 | 11.39 | -0.29 |
| APGE | Apogee Therapeutics, Inc. | $70.00 | 3.84B | — | — | — | — | -10.95 | 2.78 | — | -6.86 | -11.08 | 2.78 | 0.00% | — | — | -33.22% | -223.05% | -31.53% | 0.02 | — | 18.55 | 18.39 | 0.60 | 9880.00% | — | 12999.00% | -8.64% | -5.99 | -177.24% | 0.00% | 0.00% | 0.69% | -6.85 | -8.62 | — | 31.49 |
| CELC | Celcuity Inc. | $111.71 | 5.17B | — | — | — | — | -3.76 | 3.63 | — | -2.79 | -72.15 | 3.63 | 0.00% | — | — | -87.54% | 909.82% | -51.23% | 0.85 | -11.02 | 7.71 | 7.46 | -0.74 | 520.00% | — | 5529.00% | -19.94% | -2.63 | 672.45% | 0.00% | 0.00% | 0.00% | -2.49 | -3.38 | — | -0.09 |
| CGON | CG Oncology, Inc. Common … | $58.80 | 4.74B | +6% | +153% | — | — | -27.73 | 5.93 | 1105.21 | -23.38 | -58.37 | 6.02 | -15.02% | -4722.13% | -3985.02% | -21.67% | -4199.76% | -20.82% | 0.01 | — | 24.63 | 24.09 | 0.16 | 4752.00% | 25470.00% | 6781.00% | -2.97% | -4.29 | -2916.46% | 0.00% | 0.00% | 0.00% | -19.55 | -28.15 | 923.25 | 68.35 |
| CNTA | Centessa Pharmaceuticals … | $26.86 | 3.61B | +34% | — | — | — | -7.88 | 4.63 | — | -6.73 | -25.25 | 4.63 | 0.00% | — | — | -73.93% | -398.61% | -50.32% | 0.29 | -19.93 | 9.25 | 9.09 | 1.20 | 3121.00% | -10000.00% | -1148.00% | -7.65% | -2.45 | -281.71% | 0.00% | 0.00% | 11.98% | -7.43 | -10.51 | — | 3.81 |
| IRON | Disc Medicine, Inc. | $66.62 | 2.51B | — | — | — | — | -11.07 | 3.17 | — | -7.50 | -21.38 | 3.17 | 0.00% | — | — | -35.86% | 717.87% | -32.55% | 0.00 | -65.43 | 21.94 | 21.59 | 0.43 | 5177.00% | — | 9202.00% | -7.72% | -4.92 | 551.51% | 0.00% | 0.00% | 0.00% | -6.61 | -8.60 | — | 20.31 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| RARE | Ultragenyx Pharmaceutical… | $23.39 | 2.26B | -15% | -61% | — | — | -3.95 | -28.37 | 3.37 | -5.71 | — | -7.57 | 83.80% | -79.49% | -85.44% | -656.03% | -567.31% | -37.89% | -15.95 | -8.63 | 2.48 | 2.22 | -1.68 | -731.00% | 2013.00% | 1193.00% | -20.80% | -1.21 | -500.50% | 0.00% | 0.00% | 0.00% | -5.33 | -6.04 | 4.24 | -3.56 |
| TARS | Tarsus Pharmaceuticals, I… | $75.52 | 3.21B | +33% | +191,318% | -100% | — | -48.71 | 9.42 | 7.17 | -54.31 | — | 9.63 | 93.20% | -15.72% | -14.72% | -23.39% | -558.70% | -14.14% | 0.27 | -7.94 | 3.85 | 3.72 | 1.68 | -4821.00% | 14671.00% | -7363.00% | -0.69% | -0.09 | -175.63% | 0.00% | 0.00% | 2.09% | -41.03 | -130.51 | 6.45 | 9.02 |
| XENE | Xenon Pharmaceuticals Inc… | $43.23 | 3.34B | — | -58% | — | — | -9.75 | 5.80 | 449.63 | -8.27 | -21.74 | 5.80 | 66.09% | -4974.27% | -4612.13% | -51.76% | -419.58% | -48.34% | 0.01 | — | 13.13 | 13.17 | 0.56 | 4485.00% | — | 5175.00% | -8.30% | -6.68 | -314.81% | 0.00% | 0.00% | 1.71% | -7.59 | -10.11 | 377.51 | 35.64 |
About Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
- CEO
- Eric Dube
- Employees
- 385
- Beta
- 0.81
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($15,446.31 ÷ $44.12) − 1 = +34,909.77% (DCF, example).